Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.38 |
| ▸ | AKT2 | P31751 | 11/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867914 | 0.79 | AKT1 (0.58) | AKT1AKT2 | |
| SCHEMBL538092 | 0.77 | ADORA1 (0.39) | AKT1AKT2ADORA1ADORA2AMAPT | |
| SCHEMBL538716 | 0.77 | AKT1 (0.41) | AKT1AKT2MAPT | |
| SCHEMBL538122 | 0.77 | ALOX5 (0.43) | AKT1AKT2ADORA1ADORA3ADORA2A | |
| SCHEMBL538266 | 0.75 | AKT1 (0.40) | AKT1AKT2ADORA1ADORA3ADORA2A | |
| SCHEMBL538707 | 0.75 | MAP4K4 (0.42) | AKT1AKT2ADORA1ADORA3ADORA2A | |
| SCHEMBL539284 | 0.74 | MEN1 (0.47) | AKT1AKT2ADORA1MAPT | |
| SCHEMBL538528 | 0.73 | ADORA3 (0.40) | AKT1AKT2ADORA1ADORA3ADORA2A | |
| SCHEMBL538327 | 0.72 | KDM4E (0.38) | AKT1AKT2MAPT | |
| SCHEMBL868839 | 0.72 | AKT1 (0.56) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413932-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |